Valuation: Spectral Medical Inc.

Capitalization 24Cr 18Cr 15Cr 14Cr 13Cr 1.52TCr 27Cr 168.97Cr 65Cr 711.28Cr 66Cr 65Cr 2.61TCr P/E ratio 2025 *
-28.3x
P/E ratio 2026 * -
Enterprise value 24Cr 18Cr 15Cr 14Cr 13Cr 1.52TCr 27Cr 168.97Cr 65Cr 711.28Cr 66Cr 65Cr 2.61TCr EV / Sales 2025 *
101x
EV / Sales 2026 * 33.2x
Free-Float
68.61%
Yield 2025 *
-
Yield 2026 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day+1.19%
1 week+3.66%
Current month+4.94%
1 month-2.30%
3 months+18.06%
6 months+54.55%
Current year+70.00%
More quotes
1 week 0.79
Extreme 0.79
0.88
1 month 0.79
Extreme 0.79
0.89
Current year 0.48
Extreme 0.485
0.89
1 year 0.46
Extreme 0.455
0.89
3 years 0.22
Extreme 0.225
0.89
5 years 0.15
Extreme 0.15
0.89
10 years 0.15
Extreme 0.15
2.07
More quotes
Manager TitleAgeSince
Chief Executive Officer - 01/04/2021
Chief Tech/Sci/R&D Officer - 01/03/2021
Chief Tech/Sci/R&D Officer - -
Director TitleAgeSince
Chairman - 02/04/2024
Director/Board Member - 24/09/2014
Director/Board Member 72 31/05/2018
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
+1.19%+3.66%+63.46%+84.78% 18Cr
+0.30%+1.58%-15.11%+139.53% 71TCr
-0.50%+0.57%+4.81%-12.03% 38TCr
-1.31%+1.67%+13.27%+25.60% 34TCr
-3.64%-2.74%-54.62%+8.25% 31TCr
-2.36%-1.23%+1.86%-21.34% 26TCr
-3.00%-1.93%-3.07%+15.94% 24TCr
-1.66%+1.10%-13.64%-6.31% 22TCr
-0.79%+3.00%-35.36%-11.60% 21TCr
-1.70%-1.00%-9.17%+19.17% 16TCr
Average -1.20%+0.86%-4.76%+24.20% 28.17TCr
Weighted average by Cap. -1.25%+0.64%-11.78%+36.74%
See all sector performances

Financials

2025 *2026 *
Net sales 24L 17.53L 14.99L 13.97L 12.99L 15Cr 26.67L 1.67Cr 63.98L 7.04Cr 65.76L 64.4L 26Cr 73L 53.33L 45.6L 42.48L 39.51L 46Cr 81.13L 5.09Cr 1.95Cr 21Cr 2Cr 1.96Cr 79Cr
Net income - -
Net Debt - -
More financial data * Estimated data
Logo Spectral Medical Inc.
Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.
Employees
29
More about the company
Date Price Change Volume
11/25/11 0.8500 $ +1.19% 23,240
10/25/10 0.8400 $ -1.18% 11,500
09/25/09 0.8500 $ 0.00% 38,535
08/25/08 0.8500 $ +3.66% 32,193
07/25/07 0.8200 $ 0.00% 84,550

Delayed Quote Toronto S.E., July 12, 2025 at 01:28 am IST

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.8500CAD
Average target price
2.700CAD
Spread / Average Target
+217.65%
Consensus

Annual profits - Rate of surprise